NeuroOne Medical Technologies Corporation
Biotechnology, Health Care, Medical · 9 employees
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson’s Disease, Essential Tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
Funding history
- Funding Round — $276K — Aug 2024
- Funding Round — $12.5M — Jan 2021
- Series pre-seed — $135K — Aug 2020
- Series seed — $2.5M — May 2020
- Series seed — $1.3M — Nov 2019
Recent signals
- Nov 04, 2025: SEC 8-K (5.02): On November 4, 2025, NeuroOne Medical Technologies Corporation received a notice from The Nasdaq Stock Market granting a 180-day extension until May 4, 2026, to comply with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. This extension indicates a strategic move to retain its listing status while the company attempts to meet the compliance requirements. The notice does not affect the current listing status of the company's common stock.
- Dec 18, 2024: NeuroOne Forms Strategic Partnership Resulting in Revenue Surge
- Aug 16, 2024: Raised $276K
- Nov 18, 2023: NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan 27, 2021: Raised $12.5M
- Aug 10, 2020: Raised $135K in Series pre-seed
- May 14, 2020: Raised $2.5M in Series seed
- Nov 07, 2019: Raised $1.3M in Series seed
See plans & pricing → Track NeuroOne Medical Technologies Corporation’s funding, hiring, and signals — with verified contacts — on Fundz.